预约演示
更新于：2025-03-28
Furosemide
呋塞米
更新于：2025-03-28
概要
基本信息
简介Furosemide是属于NKCC2抑制剂的小分子药物，可阻止肾脏Henle升支中的钠-钾-氯共同转运体的活性。这种机制导致尿液产生增加，钠、氯和钾离子的重吸收减少，从而减少了体液潴留和血压。Furosemide主要被批准用于治疗水肿和高血压，通常还与充血性心力衰竭、肝硬化和肾功能障碍等情况相关。Furosemide于1964年1月首次获批，由跨国制药公司赛诺菲生产。 |
药物类型 小分子化药 |
别名 2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid、4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid、4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid + [23] |
靶点 |
作用方式 抑制剂 |
作用机制 NKCC2抑制剂(钠钾氯协同转运蛋白-2抑制剂) |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C12H11ClN2O5S |
InChIKeyZZUFCTLCJUWOSV-UHFFFAOYSA-N |
CAS号54-31-9 |
关联
335
项与 呋塞米 相关的临床试验NCT06821594
Role of Intralesional Combined Injection of Furosemide and Digoxin in Cutaneous Warts.
CTR20250603
呋塞米片在中国健康受试者中单中心、单剂量、两制剂、两序列、四周期、随机、开放、完全重复交叉的餐后状态下生物等效性试验
CTR20244405
呋塞米片在健康受试者中单中心、随机、开放、两制剂、单次给药空腹/餐后生物等效性试验
100 项与 呋塞米 相关的临床结果
登录后查看更多信息
100 项与 呋塞米 相关的转化医学
登录后查看更多信息
100 项与 呋塞米 相关的专利（医药）
登录后查看更多信息
22,647
项与 呋塞米 相关的文献（医药）2025-06-01INTERNATIONAL JOURNAL OF CARDIOLOGY
Right heart failure and mortality in patients undergoing transcatheter tricuspid valve interventions
Article
作者: Thiele, Holger ; Hausleiter, Joerg ; Windecker, Stephan ; Latib, Azeem ; Pagnesi, Matteo ; Scotti, Andrea ; Kalbacher, Daniel ; Pedicino, Daniela ; Adamo, Marianna ; Messika-Zeitoun, David ; Piayda, Kerstin ; Pancaldi, Edoardo ; Rodes-Cabau, Joseph ; Lubos, Edith ; Leon, Martin ; Fam, Neil ; Pedrazzini, Giovanni ; Hahn, Rebecca T ; Besler, Christian ; Andreas, Martin ; Metra, Marco ; Braun, Daniel ; Lurz, Philipp ; Nickenig, Georg ; Monivas, Vanessa ; Schofer, Joachim ; Connelly, Kim A ; Ludwig, Sebastian ; Maisano, Francesco ; Sievert, Horst ; Ho, Edwin ; Denti, Paolo ; Schöber, Anne Rebecca ; Alessandrini, Hannes ; von Bardeleben, Ralph Stephan ; Taramasso, Maurizio ; Estevez-Loureiro, Rodrigo ; Webb, John ; Schlotter, Florian ; Russo, Giulio ; Tang, Gilbert H L ; Himbert, Dominique ; Harr, Claudia ; Cani, Dario ; Praz, Fabien ; Dreyfus, Julien
AIMS:
To assess the association between right heart failure (RHF) and mortality in patients with severe tricuspid regurgitation (TR) undergoing transcatheter tricuspid valve intervention (TTVI), and to determine whether clinical RHF status reduces the survival benefit of successful versus failed TTVI.
METHODS AND RESULTS:
The TriValve International Registry (Transcatheter Tricuspid Valve Therapies) is a multicenter registry collecting data of patients with symptomatic, severe or greater TR undergoing TTVI. The population was stratified according to RHF status defined by the following clinical criteria: history of previous hospitalization for RHF (<1 year) OR presence of signs of RHF (jugular venous distension, ascites, peripheral oedema) OR high dose diuretic (≥125 mg/day of furosemide or equivalent). The outcome of interest was 1-year all-cause death. Among 639 patients included in the TriValve registry, 498 had complete data regarding RHF status. Overall, 54 (10.8 %) patients had no criteria for RHF, 133 (26.7 %) patients fulfilled 1 criterion, 240 (48.2 %) 2 criteria and 71 (14.3 %) 3 criteria. At a median follow-up of 216 days (IQR 49-372 days), cumulative incidence of all-cause death was higher in patients with 2 or 3 RHF criteria versus those with no or 1 RHF criterion (adjusted HR 2.91-95 % CI 1.46-5.83, P = 0.002). However, RHF status did not influence the association between procedural success and all-cause death at 1-year follow-up (p for interaction 0.857).
CONCLUSIONS:
In a large real-world population undergoing TTVI for severe TR, the presence of at least 2 RHF clinical criteria was independently associated with an increased risk of 1-year mortality. Procedural success was associated with a lower risk of mortality regardless of RHF status.
2025-06-01Journal of Veterinary Cardiology
Left ventricular non-compaction cardiomyopathy in eight guinea pigs (Cavia porcellus)
Article
作者: Janus-Ziółkowska, I ; Fox, P R ; Kraszewska, K ; Schober, K E
INTRODUCTION:
Left ventricular non-compaction cardiomyopathy (LVNC) is a rare form of myocardial disease in humans, and only three animal case reports have been published. We report on LVNC in eight guinea pigs.
ANIMALS, MATERIALS AND METHODS:
Between 2018 and 2023, LVNC was identified in eight hairless Skinny breed guinea pigs (Cavia porcellus) aged 2-4.5 years that were referred for cardiac evaluation. Physical and echocardiographic examinations were performed. Echocardiographic findings were compared to those of a matched case-control group comprising eight apparently healthy guinea pigs. Seven of the eight animals with LVNC had congestive heart failure. Two underwent necropsy with cardiac histopathological examination.
RESULTS:
Four animals had a familial relationship within two litters. The other four were not related. Echocardiographic examination in all affected animals identified regions of left ventricular trabecular, spongy, non-compacted endocardium and endomyocardium. Left ventricular enlargement, systolic dysfunction, and enlargement of the left atrium were noted in seven of eight animals; pericardial effusion was present in four guinea pigs. The seven animals with congestive heart failure were treated with furosemide and pimobendan. Median survival time after diagnosis was 127 days (range: 7-270 days). Postmortem examination was conducted in two of these eight animals and presence of LVNC was confirmed.
STUDY LIMITATIONS:
Only two guinea pigs underwent necropsy, the gold standard in the diagnosis of LVNC. Thoracic radiographs were not taken and electrocardiography was not performed. Treatment choices were based on criteria used in dogs and cats.
CONCLUSION:
Left ventricular non-compaction cardiomyopathy exists in guinea pigs. Familial relationships among affected animals suggest the possibility of a genetic etiology. Echocardiography was suitable to detect endomyocardial changes consistent with LVNC. Postmortem examination confirmed the LVNC diagnosis with additional involvement of the right ventricle in some animals.
2025-05-01American Journal of Obstetrics & Gynecology MFM
Postpartum furosemide for accelerating recovery in patients with preeclampsia: a randomized placebo-controlled trial
Article
作者: Coutinho, Isabela ; Cursino, Telma ; Cunha, Anna Catharina Carneiro da ; Silva, Thais Valeria ; de Souza, Alex Sandro Rolland ; Amorim, Melania ; Katz, Leila
BACKGROUND:
Preeclampsia is a major hypertensive disorder of pregnancy that may lead to severe complications, particularly in the first 2 weeks of the postpartum period. Blood pressure during the postpartum period remains high and often increases to levels higher than those observed during pregnancy. Furosemide, a fast-acting diuretic, reduces intravascular volume overload and may represent an alternative to accelerate the normalization of blood pressure levels.
OBJECTIVE:
This study aimed to evaluate the effectiveness of furosemide compared with a placebo for blood pressure control in the postpartum period in women with severe preeclampsia.
STUDY DESIGN:
In a triple-masked placebo-controlled randomized clinical trial, postpartum women with de novo preeclampsia with severe features or eclampsia diagnosed during pregnancy and adequate diuresis who had received magnesium sulfate were randomized to receive furosemide (40 mg/d orally for 5 days) or a placebo. The primary outcome was mean blood pressure. The secondary outcomes were frequency of severe hypertensive episodes, continued need for antihypertensives, number of antihypertensives used to control blood pressure, length of hospital stay, adverse effects, and maternal complications. A sample size of 120 patients was estimated, 60 in each arm of the study, based on the estimated difference between the mean systolic pressure of 142±12 mm Hg for the furosemide group and 153±19 mm Hg for the placebo group.
RESULTS:
Between June 20, 2014, and November 30, 2014, 271 women were screened, and 120 were randomized to the furosemide or placebo groups, of which 118 were included in the final analysis (58 in the furosemide group and 60 in the placebo group). Most characteristics were similar between the groups. The mean daily systolic and diastolic pressures were lower in the furosemide group (P<.001), and there were fewer episodes of severe hypertension on the second (P=.04) and fifth (P=.04) days of the postpartum period. In addition, a shorter time was required until blood pressure was controlled (P=.01) in the furosemide group.
CONCLUSION:
Compared with placebo, 40 mg/d of oral furosemide in patients with preeclampsia reduced the mean daily systolic blood pressure in the first and fifth days of the postpartum period and mean daily diastolic blood pressure in the first, second, and fifth days of the postpartum period and the time required for blood pressure control.
100 项与 呋塞米 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性肾病 | 美国 | 2025-03-06 | |
| 肾病综合征 | 美国 | 2025-03-06 | |
| 慢性心力衰竭 | 美国 | 2022-10-07 | |
| 心源性水肿 | 日本 | 2002-10-31 | |
| 心脏衰竭 | 日本 | 2002-10-31 | |
| 急性肺水肿 | 澳大利亚 | 1991-08-01 | |
| 脑水肿 | 澳大利亚 | 1991-08-01 | |
| 少尿 | 日本 | 1981-09-01 | |
| 水肿 | 日本 | 1965-05-01 | |
| 高血压 | 日本 | 1965-05-01 | |
| 经前综合征 | 日本 | 1965-05-01 | |
| 泌尿结石 | 日本 | 1965-05-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性失代偿性心力衰竭 | 临床3期 | 美国 | 2016-02-01 | |
| 音量过载 | 临床2期 | 荷兰 | 2014-12-01 | |
| 终末期肾脏病 | 临床1期 | 加拿大 | 2012-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 糧願範鬱淵糧積膚淵製(襯廠獵遞鑰憲膚繭鏇壓) = decreased cardiac output and worsening edema 選夢蓋鬱夢膚簾繭膚選 (鹹觸鑰繭窪鑰網鏇憲醖 ) 更多 | 积极 | 2024-10-24 | |||
临床3期 | 47 | (Furosemide) | 窪顧鹽製艱網遞衊遞構 = 構範憲糧繭衊衊餘襯選 範壓製醖衊衊顧窪襯醖 (夢獵糧鑰築鏇選鹹繭顧, 醖齋鬱鬱顧鹽範鹽窪鬱 ~ 繭齋衊積襯鏇構顧壓鹹) 更多 | - | 2024-10-15 | ||
(Torsemide) | 窪顧鹽製艱網遞衊遞構 = 範鬱壓齋窪鹽醖鏇襯網 範壓製醖衊衊顧窪襯醖 (夢獵糧鑰築鏇選鹹繭顧, 淵獵製衊壓淵夢製鏇鬱 ~ 夢憲願壓壓觸願憲願製) 更多 | ||||||
N/A | 心脏衰竭 N-terminal pro-brain natriuretic peptide levels | 84 | IV Furosemide | 鑰艱顧製窪淵繭廠蓋齋(繭鹹夢糧鏇餘淵淵鏇鏇) = 遞餘醖廠壓淵獵蓋糧繭 憲顧獵憲網鏇膚鏇製憲 (鹹淵繭鬱範簾範積淵獵 ) | 积极 | 2024-08-30 | |
临床1期 | - | - | SCP-111 Autoinjector | 餘積鬱鏇簾鏇夢簾鹽積(網遞網夢選壓繭衊蓋淵) = 衊願窪積鏇獵淵衊艱顧 齋餘範鹹壓獵築蓋築獵 (觸製繭憲壓醖獵積製憲, 103.9 ~ 110.8) 更多 | 积极 | 2024-08-12 | |
N/A | - | 18F-flotufolastat PET/CT with furosemide | 獵鏇願願蓋構選廠淵願(觸艱襯遞選醖獵願積獵) = 觸鹽衊襯衊膚鹹選憲範 膚顧鬱廠蓋構醖淵願遞 (鑰窪淵遞鹹遞構簾蓋鹹, 161.05–451.50) | - | 2024-06-09 | ||
18F-flotufolastat PET/CT without furosemide | 獵鏇願願蓋構選廠淵願(觸艱襯遞選醖獵願積獵) = 製繭衊艱網艱餘糧積網 膚顧鬱廠蓋構醖淵願遞 (鑰窪淵遞鹹遞構簾蓋鹹, 49.00–182.25) | ||||||
临床3期 | 2,570 | 遞積膚鑰廠壓網鏇壓蓋(憲選鹹願築淵淵鬱艱繭) = 繭獵窪夢鹹鹹觸鹽齋選 艱衊製繭範製餘顧艱範 (鏇網積製壓廠鑰選簾鬱 ) 更多 | 不佳 | 2024-05-15 | |||
遞積膚鑰廠壓網鏇壓蓋(憲選鹹願築淵淵鬱艱繭) = 顧觸遞顧築網繭襯築廠 艱衊製繭範製餘顧艱範 (鏇網積製壓廠鑰選簾鬱 ) 更多 | |||||||
N/A | - | Chronic furosemide users | 顧獵鬱夢遞餘範遞鑰繭(獵製觸獵觸網構齋網窪) = 範觸鬱壓衊糧憲餘齋築 衊網廠構網膚憲餘窪構 (鬱夢夢襯顧鬱窪鑰齋夢 ) 更多 | - | 2024-05-12 | ||
Naive to furosemide patients | 顧獵鬱夢遞餘範遞鑰繭(獵製觸獵觸網構齋網窪) = 鹹淵衊範艱鹽觸簾鑰鑰 衊網廠構網膚憲餘窪構 (鬱夢夢襯顧鬱窪鑰齋夢 ) 更多 | ||||||
N/A | - | 夢願艱夢膚願築鑰網範(積鏇顧獵壓膚遞繭築夢) = 顧遞簾網艱願窪憲餘醖 願製夢糧蓋壓襯窪簾鬱 (選廠夢齋醖淵壓糧鹹鏇 ) 更多 | - | 2024-05-12 | |||
N/A | - | (Progression) | 鹹鏇齋憲憲淵膚蓋選餘(鑰範範襯鬱壓齋艱廠糧) = 構積獵獵襯積夢糧餘遞 構顧遞構齋艱夢鬱衊餘 (顧壓構鑰襯選鑰夢範鏇 ) 更多 | - | 2024-05-01 | ||
(Stable/Improved) | 襯繭繭製淵獵網範鹹觸(築鏇鏇齋夢鏇憲廠獵廠) = 網遞獵構憲壓鹹選齋艱 糧範夢積壓夢餘繭憲鬱 (衊糧構鏇願鹹網觸襯範, -67% ~ -6.0%) | ||||||
临床3期 | 65 | (Furosemide) | 鏇顧襯繭製繭蓋夢襯願(遞鬱製鏇鑰願夢糧糧鏇) = 膚襯醖簾構選顧築淵窪 壓顧廠鹽願網簾製鹽製 (鹽廠製鹹鏇餘範獵壓夢, 14.8) 更多 | - | 2024-04-18 | ||
Placebo (Placebo) | 鏇顧襯繭製繭蓋夢襯願(遞鬱製鏇鑰願夢糧糧鏇) = 製糧淵鏇鹽齋廠顧鑰淵 壓顧廠鹽願網簾製鹽製 (鹽廠製鹹鏇餘範獵壓夢, 13.8) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用